Dermacyte AC Matrix is a full thickness amnion-chorion allograft. It is an allogeneic matrix cellular and tissue-based skin substitute for wound healing.
INTENDED USES: Dermacyte AC Matrix is intended for use as a protective covering or barrier.
CLAIMED BENEFITS: Lyophilized for application with no refrigeration. No preparation time required for thawing or soaking. Conforms to wound bed and naturally hydrates in place. Handling and protein retention properties protect from tissue defects. Routine dressing changes, wound cleansing, and Dermacyte reapplication allows for assessment of wound closure.
The addition of Skin Substitutes or Cellular or Tissue Based Products (CTPs) to certain wounds may afford a healing advantage over dressings and conservative treatments when these options appear insufficient to affect complete healing, after at least a 30 day period of comprehensive conservative therapy. There are currently a wide variety of bioengineered products available for soft tissue coverage to affect closure. • Human skin allografts are derived from donated human skin (cadavers) • Allogeneic matrices are derived from human tissue (fibroblasts or membrane) • Composite matrices are derived from human keratinocytes, fibroblasts and xenogeneic collagen • Acellular matrices are derived from xenogeneic collagen or tissue
For Medicare to cover this product, it needs to be ordered and applied by your clinician. A patient cannot purchase it directly from a Durable Medical Equipment (DME) store and receive reimbursement for it.
An invitation to view this topic will be emailed to specified recipients.
Sorry, this content is only available to registered members. Please register for FREE account to gain access.
To access this premium feature and more, upgrade to a premium plan today. Or browse to enjoy free content and tools.
WoundReference is a clinical decision support platform for experienced and new wound care clinicians at the point-of-care